https://www.selleckchem.com/products/sr-717.html
78; 95% confidence interval, 1.05-3.03; P = .015) and ≥ 3 metastatic sites (hazard ratio, 3.97; 95% confidence interval, 1.97-8.01; P less then .001) were independently correlated with poor PFS. Patients with irAE and patients without interstitial lung disease had significantly longer PFS (14.0 and 4.9 months, respectively; P = .011) than patients without irAE or patients with interstitial lung disease. CONCLUSION The outcome of patients receiving first-line pembrolizumab treatment was worse in those with nonadenocarcinoma and with a lar
Like
Comment
Share
